NCT01301963 · ADVERSE EVENTS

Adverse events

Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide · Source last updated 2014-08-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: Not reported
Other-event reporting threshold: 5%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Arm I: Control Patients receive G-CSF SC QD on days 1-4. filgrastim: Given SC	0 / 5	0 / 5	Not reported / Not reported
Arm II: Experimental Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8. plerixafor: Given SC filgrastim: Given SC	0 / 4	0 / 4	Not reported / Not reported

Group identifiers: EG000: Arm I: Control · EG001: Arm II: Experimental

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

event Groups

description
Patients receive G-CSF SC QD on days 1-4. filgrastim: Given SC
id
EG000
other Num Affected
0
other Num At Risk
5
serious Num Affected
0
serious Num At Risk
5
title
Arm I: Control
description
Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8. plerixafor: Given SC filgrastim: Given SC
id
EG001
other Num Affected
0
other Num At Risk
4
serious Num Affected
0
serious Num At Risk
4
title
Arm II: Experimental

frequency Threshold

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice